JP6927875B2 - 抗ｍｅｔ抗体および組成物 - Google Patents

抗ｍｅｔ抗体および組成物 Download PDF

Info

Publication number
JP6927875B2
JP6927875B2 JP2017514687A JP2017514687A JP6927875B2 JP 6927875 B2 JP6927875 B2 JP 6927875B2 JP 2017514687 A JP2017514687 A JP 2017514687A JP 2017514687 A JP2017514687 A JP 2017514687A JP 6927875 B2 JP6927875 B2 JP 6927875B2
Authority
JP
Japan
Prior art keywords
antibody
amino acid
met
seq
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017514687A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017534259A (ja
JP2017534259A5 (esLanguage
Inventor
トーマス・ボーキン
ミッケル・ヴァンダール・ペダーセン
ヘレ・イェーネ・ヤコブセン
トーマス・トゥクセン・ポウルセン
ミカエル・モンラズ・グランダル
クラウス・コフォーズ
ミカエル・クラウ
カーステン・ヴェッセル・エリクセン
パオロ・コンロット
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Symphogen AS
Original Assignee
Symphogen AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symphogen AS filed Critical Symphogen AS
Publication of JP2017534259A publication Critical patent/JP2017534259A/ja
Publication of JP2017534259A5 publication Critical patent/JP2017534259A5/ja
Application granted granted Critical
Publication of JP6927875B2 publication Critical patent/JP6927875B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
JP2017514687A 2014-09-16 2015-09-15 抗ｍｅｔ抗体および組成物 Active JP6927875B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462051190P 2014-09-16 2014-09-16
US62/051,190 2014-09-16
PCT/IB2015/002110 WO2016042412A1 (en) 2014-09-16 2015-09-15 Anti-met antibodies and compositions

Publications (3)

Publication Number Publication Date
JP2017534259A JP2017534259A (ja) 2017-11-24
JP2017534259A5 JP2017534259A5 (esLanguage) 2018-10-18
JP6927875B2 true JP6927875B2 (ja) 2021-09-01

Family

ID=54780359

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017514687A Active JP6927875B2 (ja) 2014-09-16 2015-09-15 抗ｍｅｔ抗体および組成物

Country Status (11)

Country Link
US (1) US10450376B2 (esLanguage)
EP (1) EP3194444B1 (esLanguage)
JP (1) JP6927875B2 (esLanguage)
KR (1) KR102200274B1 (esLanguage)
CN (1) CN107001471B (esLanguage)
AU (1) AU2015316522B2 (esLanguage)
CA (1) CA2961323C (esLanguage)
ES (1) ES2748295T3 (esLanguage)
IL (1) IL250902B (esLanguage)
MX (1) MX378108B (esLanguage)
WO (1) WO2016042412A1 (esLanguage)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018014175A (es) 2016-05-17 2020-02-07 Abbvie Biotherapeutics Inc Conjugados de anticuerpo-fármaco anti-cmet y métodos para su uso.
BR112019005783A2 (pt) 2016-09-29 2019-06-18 Mitsubishi Tanabe Pharma Corporation agentes de ligação monoclonal com cmet, conjugados de fármaco dos mesmos e usos dos mesmos
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
US20200129633A1 (en) 2017-06-06 2020-04-30 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition comprising c-met antibody-drug conjugate and use thereof
US12060427B2 (en) * 2018-03-28 2024-08-13 Mitsubishi Tanabe Pharma Corporat Drug conjugates of cMET monoclonal binding agents, and uses thereof
KR102221755B1 (ko) * 2018-05-02 2021-03-02 (주)에임드바이오 c-Met에 특이적으로 결합하는 항체 및 그의 용도
KR102433184B1 (ko) * 2018-12-07 2022-08-17 서울대학교 산학협력단 항 c-Met 아고니스트 항체 및 이의 용도
US20230295313A1 (en) * 2019-06-26 2023-09-21 Glaxosmithkline Intellectual Property Development Limited Il1rap binding proteins
CN121015920A (zh) 2019-09-16 2025-11-28 瑞泽恩制药公司 用于免疫pet成像的放射性标记的met结合蛋白
WO2021058735A1 (en) 2019-09-26 2021-04-01 Symphogen A/S Cancer treatment with anti-met antibody compositions
WO2022204332A1 (en) * 2021-03-24 2022-09-29 Combangio, Inc. Compositions comprising c-met agonist antibodies and methods for use in ocular treatment
KR20230166099A (ko) 2021-04-08 2023-12-06 비온디스 비.브이. 항-c-met 항체 및 항체-약물 접합체
WO2023150632A2 (en) * 2022-02-02 2023-08-10 The Broad Institute, Inc. Targeting moieties promoting transduction of central nervous system cells and tissues and methods of use
CA3256012A1 (en) 2022-05-20 2023-11-23 Les Laboratoires Servier ANTIBODY-DRUG CONJUGATES, MET INHIBITORS BCL-XL, AND THEIR METHODS OF USE
AR132710A1 (es) 2023-05-19 2025-07-23 Servier Lab Anticuerpos anti-met, adc, composiciones y usos de los mismos

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
WO1986005807A1 (en) 1985-04-01 1986-10-09 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
ES2330052T3 (es) 1991-03-01 2009-12-03 Dyax Corporation Proteina quimerica que comprende micro-proteinas que tienen dos o mas puentes disulfuro y relaizaciones de las mismas.
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
CA2119930C (en) 1991-09-23 2002-10-01 Hendricus R. J. M. Hoogenboom Production of chimeric antibodies - a combinatorial approach
CA2144856A1 (en) 1992-09-18 1994-03-31 Donna L. Faletto A method of preventing tumor metastasis
DE69424687T2 (de) 1993-03-09 2000-09-07 Genzyme Corp., Cambridge Verfahren zur isolierung von proteinen aus milch
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5707624A (en) 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor
US6046037A (en) 1994-12-30 2000-04-04 Hiatt; Andrew C. Method for producing immunoglobulins containing protection proteins in plants and their use
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US6214344B1 (en) 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
JP2000515735A (ja) 1996-07-03 2000-11-28 ジェネンテック インコーポレーテッド 肝細胞成長因子レセプターアゴニスト
JP2002512624A (ja) 1997-05-21 2002-04-23 バイオベーション リミテッド 非免疫原性タンパク質の製造方法
WO2000009560A2 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
ATE352559T1 (de) 1998-12-08 2007-02-15 Biovation Ltd Verfahren zur verminderung der immunogenität von proteinen
US6517529B1 (en) 1999-11-24 2003-02-11 Radius International Limited Partnership Hemodialysis catheter
CA2512647C (en) 2003-01-07 2013-10-08 Symphogen A/S Method for manufacturing recombinant polyclonal proteins
ITMI20031127A1 (it) 2003-06-05 2004-12-06 Uni Degli Studi Del Piemont E Orientale Am Anticorpi anti-hgf-r e loro uso
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
TWI333977B (en) 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
KR101201464B1 (ko) 2004-05-05 2012-11-14 메리맥 파마슈티컬즈, 인크. 생물학적 활성을 조정하기 위한 이특이성 결합제
US7476724B2 (en) 2004-08-05 2009-01-13 Genentech, Inc. Humanized anti-cmet antibodies
US7615529B2 (en) 2005-03-25 2009-11-10 Genentech, Inc. Methods and compositions for modulating hyperstabilized c-met
ATE541584T1 (de) 2005-11-16 2012-02-15 Fariba Nayeri Verfahren zur hemmung von krebsbildung und/oder metastasen bei einer person durch endogene c-met- liganden und -hemmer
PT1981981E (pt) 2006-02-06 2011-10-04 Metheresis Translational Res Sa Anticorpos monoclonais anti-met, fragmentos e vectores destes, para o tratamento de tumores e produtos correspondentes
EP1997511B1 (en) 2006-03-20 2011-07-20 Seikagaku Corporation Therapeutic agent for rheumatoid arthritis
AU2007245181A1 (en) 2006-03-30 2007-11-08 Novartis Ag Compositions and methods of use for antibodies of c-Met
US8039598B2 (en) 2007-01-19 2011-10-18 Van Andel Research Institute Met fab and SCFV fragments
CA2683800C (en) 2007-05-25 2015-03-17 Symphogen A/S Method for manufacturing a recombinant polyclonal protein
EP2014681A1 (en) 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
US7892770B2 (en) 2007-08-24 2011-02-22 Van Andel Research Institute Monoclonal antibody which binds cMet (HGFR) in formalin-fixed and paraffin-embedded tissues and related methods
CN102007146A (zh) 2008-04-23 2011-04-06 西福根有限公司 用于制备多克隆蛋白质的方法
US8455623B2 (en) 2008-05-21 2013-06-04 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
JP2012504961A (ja) * 2008-10-06 2012-03-01 ミネルバ バイオテクノロジーズ コーポレーション Ｍｕｃ１＊抗体
PA8849001A1 (es) * 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
JP6055312B2 (ja) 2010-03-10 2017-01-11 ゲンマブ エー／エス Ｃ−ｍｅｔに対するモノクローナル抗体
EP2635604B1 (en) 2010-11-01 2016-11-30 Symphogen A/S Pan-her antibody composition
EP2635602B1 (en) 2010-11-03 2016-09-07 Argen-X Nv Anti c-met antibodies

Also Published As

Publication number Publication date
AU2015316522B2 (en) 2021-01-21
AU2015316522A1 (en) 2017-03-23
EP3194444B1 (en) 2019-07-10
US10450376B2 (en) 2019-10-22
KR102200274B1 (ko) 2021-01-08
CA2961323A1 (en) 2016-03-24
ES2748295T3 (es) 2020-03-16
MX2017003211A (es) 2017-06-06
MX378108B (es) 2025-03-10
IL250902A0 (en) 2017-04-30
BR112017005202A2 (pt) 2017-12-12
JP2017534259A (ja) 2017-11-24
US20180327500A1 (en) 2018-11-15
IL250902B (en) 2022-08-01
EP3194444A1 (en) 2017-07-26
CN107001471B (zh) 2022-01-18
WO2016042412A1 (en) 2016-03-24
KR20170054517A (ko) 2017-05-17
CN107001471A (zh) 2017-08-01
CA2961323C (en) 2021-11-30

Similar Documents

Publication Publication Date Title
JP6927875B2 (ja) 抗ｍｅｔ抗体および組成物
TWI784976B (zh) 抗ｌａｇ-３抗體及組成物
TWI751981B (zh) 抗pd-1抗體及組成物
JP5896993B2 (ja) ヒトｇｄｆ８に対する抗体
JP6457431B2 (ja) 抗アクチビンａ抗体およびその使用
TWI528974B (zh) 用於增加肌肉生長之組合物及方法
TWI583700B (zh) 抗表皮生長因子受體（ｅｇｆｒ）之抗體及其用途
TWI426083B (zh) 重組抗表皮生長因子受體抗體組成物
JP5701876B2 (ja) ヒトアンジオポイエチン−２に対する高親和性ヒト抗体
PT2129396E (pt) Anticorpos contra erbb3 e suas utilizações
JP2010502740A5 (esLanguage)
CN102481365A (zh) 用dll4拮抗剂和化疗剂治疗癌症的方法
JP2018532715A (ja) 抗ｔｆ抗体薬物コンジュゲートの投薬レジメン
JP2024079697A (ja) 骨の疾患の治療に用いるためのトランスフェリン受容体２のアンタゴニスト及びアゴニスト
JP2024511853A (ja) Ｇｄｆ１５シグナル伝達の治療的阻害剤
EP3164416A1 (en) Therapy for gist
BR112017005202B1 (pt) Anticorpo anti-met ou uma porção de ligação antigênica do mesmo, composição, seus métodos de produção, e uso
US20230062308A1 (en) Treatment of ck8 positive cancers in relation with k-ras gene status
KR20260016936A (ko) 항-met 항체, 항체-약물 접합체, 조성물 및 그의 용도
TW202500584A (zh) 抗met抗體、抗體-藥物結合物、組合物及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180910

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180910

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190716

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190723

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200807

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210202

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210706

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210805

R150 Certificate of patent or registration of utility model

Ref document number: 6927875

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250